Sharda Cropchem Limited has reported exceptional financial performance for the quarter and year ended March 31, 2026. The company achieved a record annual Profit After Tax (PAT) of ₹681 crore, reflecting a 124% year-on-year growth. Revenue for the full fiscal year surged by 22% to ₹5,268 crore, driven by strong volume growth across major international markets, including Europe and Latin America, alongside improved operational efficiencies.
Fiscal Year 2026 Financial Performance
Sharda Cropchem concluded FY26 with strong financial momentum. The company reported a total annual revenue of ₹5,268 crore, representing a 22% increase compared to the previous year. This growth was primarily fueled by a 13.3% rise in agrochemical volumes and a 15.3% growth in non-agrochemical volumes. Operational efficiency was a major highlight, with Gross Margins expanding by 600 basis points to 35.9%, leading to an EBITDA of ₹1,040 crore, a significant 69% growth over FY25.
Quarterly Highlights
For the final quarter (Q4 FY26), the company reported revenues of ₹2,065 crore, marking a 13% increase year-on-year. The quarter saw particularly strong performance in the agrochemical segment, which now accounts for 93% of the total revenue. Notably, EBITDA for the quarter rose by 75% to ₹513 crore, with PAT reaching ₹319 crore, a 57% increase compared to the same period in the previous year.
Strategic Market Expansion
The company continues to leverage its asset-light business model to maintain scalability and capital efficiency. With a vast library of 3,011 active registrations and 1,004 applications pending, Sharda Cropchem has solidified its presence in over 80 countries. Geographic growth in FY26 was led by a strong 37% revenue increase in Europe and a 33% rise in Latin America, reflecting the success of the company’s focus on diversifying its regional footprint.
Balance Sheet Strength
The company maintains a healthy financial position with total equity standing at ₹3,137 crore as of March 31, 2026. Furthermore, the company successfully reduced its working capital requirements by 20 days, improving overall liquidity. These results underscore the effectiveness of the company’s focus on operational efficiencies, margin improvements, and its strategic commitment to identifying and registering off-patent generic molecules globally.
Source: BSE
